Sergiusz Nawrocki

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial

Charles Butts, Mark A. Socinski, Paul Mitchell et al. · The Lancet Oncology · 2013 · 526 citations · Full text

Medicine, Oncology, Pharmacology +13

Expression of interleukin-6, interleukin-6 receptor, and glycoprotein 130 correlates with good prognoses for patients with breast carcinoma

Aldona Karczewska, Sergiusz Nawrocki, Danuta Br borowicz et al. · Cancer · 2000 · 59 citations · Full text

Medicine, Cancer Biology, Oncology +13

START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer.

Charles Butts, Mark A. Socinski, Paul Mitchell et al. · Journal of Clinical Oncology · 2013 · 59 citations

Medicine, Oncology, Pharmacology +14

Comparative Aquatic Toxicity Evaluation of 2-(Thiocyanomethylthio)benzothiazole and Selected Degradation Products Using Ceriodaphnia dubia

Sergiusz Nawrocki, K.D. Drake, Carl F. Watson et al. · Archives of Environmental Contamination and Toxicology · 2005 · 56 citations

Veterinary Medicine, Environmental Sciences, Toxicology +14

Concurrent Chemotherapy and Short Course Radiotherapy in Patients with Stage IIIA to IIIB Non-small Cell Lung Cancer Not Eligible for Radical Treatment: Results of a Randomized Phase II Study

Sergiusz Nawrocki, Maciej Krzakowski, Ewa Wasilewska-Teśluk et al. · Journal of Thoracic Oncology · 2010 · 32 citations · Full text

Medicine, Oncology, Chemotherapy +14